Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 27,107 shares of the company’s stock in a transaction that occurred on Tuesday, June 8th. The stock was sold at an average price of $1.75, for a total transaction of $47,437.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Athersys stock opened at $1.62 on Friday. Athersys, Inc. has a 52-week low of $1.40 and a 52-week high of $3.30. The stock has a fifty day simple moving average of $1.68. The firm has a market capitalization of $359.78 million, a price-to-earnings ratio of -3.60 and a beta of -1.67.
Athersys (NASDAQ:ATHX) last released its quarterly earnings data on Wednesday, May 5th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.05). On average, sell-side analysts anticipate that Athersys, Inc. will post -0.36 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in ATHX. Cambridge Investment Research Advisors Inc. increased its position in shares of Athersys by 7.6% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 63,857 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 4,507 shares in the last quarter. BlackRock Inc. increased its position in shares of Athersys by 4.0% in the fourth quarter. BlackRock Inc. now owns 13,712,668 shares of the biopharmaceutical company’s stock worth $23,999,000 after acquiring an additional 533,510 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Athersys by 80.7% in the fourth quarter. ProShare Advisors LLC now owns 38,421 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 17,160 shares during the period. Blair William & Co. IL boosted its stake in shares of Athersys by 8.9% in the fourth quarter. Blair William & Co. IL now owns 58,300 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 4,750 shares during the period. Finally, Aurum Wealth Management Group LLC purchased a new position in shares of Athersys in the fourth quarter valued at $38,000. 26.72% of the stock is owned by institutional investors.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Featured Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.